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Abstract
Background: Short-chain fructo-oligosaccharides (scFOS) are increasingly used in human diet for
their prebiotic properties. We aimed at investigating the effects of scFOS ingestion on the colonic
microflora and oro-fecal transit time in elderly healthy humans.
Methods: Stools composition, oro-fecal transit time, and clinical tolerance were evaluated in 12
healthy volunteers, aged 69 ± 2 yrs, in three consecutive periods: basal period (2 weeks), scFOS
(Actilight®) ingestion period (8 g/d for 4 weeks) and follow-up period (4 weeks). Two-way
ANOVA, with time and treatment as factors, was used to compare the main outcome measures
between the three periods.
Results: Fecal bifidobacteria counts were significantly increased during the scFOS period (9.17 ±
0.17 log cfu/g vs 8.52 ± 0.26 log cfu/g during the basal period) and returned to their initial values at
the end of follow-up (8.37 ± 0.21 log cfu/g; P < 0.05). Fecal cholesterol concentration increased
during the scFOS period (8.18 ± 2.37 mg/g dry matter vs 2.81 ± 0.94 mg/g dry matter during the
basal period) and returned to the baseline value at the end of follow-up (2.87 ± 0.44 mg/g dry
matter; P < 0.05). Fecal pH tended to decrease during scFOS ingestion and follow-up periods
compared to the basal period (P = 0.06). Fecal bile acids, stool weight, water percentage, and oro-
fecal transit time did not change throughout the study. Excess flatus and bloating were significantly
more frequent during scFOS ingestion when compared to the basal period (P < 0.05), but the
intensity of these symptoms was very mild.
Conclusion: Four-week 8 g/d scFOS ingestion is well tolerated and leads to a significant increase
in fecal bifidobacteria in healthy elderly subjects. Whether the change in cholesterol metabolism
found in our study could exert a beneficial action warrants further studies.
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Background
Short-chain fructo-oligosaccharides (scFOS) are a mixture
of oligosaccharides consisting of glucose linked to fruc-
tose units [1]. They are poorly absorbed in the human
small intestine [2], but are fermented in the colon by the
resident microflora [3]. It is now well established that
scFOS meet criteria to be considered as prebiotic, defined
as a non digestible food ingredient that beneficially affects
the host by selectively stimulating growth and/or activity
of one or a limited number of colonic bacteria, and thus
improves host health [4]. We have shown in humans that
dietary addition of 10 g/d scFOS led to increasing fecal
counts of bifidobacteria [5]; moreover, the scFOS admin-
istration dose-dependently increases fecal bifidobacteria
in healthy volunteers, with an optimal and well-tolerated
dose ranging from 2.5 to 10 g/d [6,7].
Bifidobacteria are considered beneficial to health [8], even
if sound evidence of such effect is not available yet [4]. In
mice,  in vivo administered bifidobacteria along with
fructo-oligosaccharides reduced 1,2-dimethylhydrazine
induced carcinogenesis [9]. In rats, Bifidobacterium longum,
administered alone or in association with non-digestible
oligosaccharides, exerts strong antitumour activity [10,11]
This effect could be due to colon acidification that inhibits
bacterial degradation of primary to carcinogenic second-
ary bile acids [12] and/or to increasing bifidobacteria pop-
ulation. Indeed, bifidobacteria per se could have an anti-
tumorigenic activity. Bifidobacteria reduce nitrosamine
mutagenicity, and Bifidobacterium bifidum administered
along with Lactobacillus acidophilus to healthy humans
decreases nitroreductase activity in stools [13]. Lastly, oli-
gosaccharide ingestion could result in increasing colonic
contents and decreasing transit time [14], both factors
may affect colonic carcinogen concentration and mucosal
contact time [15]. Thus, taking into account the intrinsic
anti-tumoral properties of bifidobacteria and the effects
on colonic pH, fecal mass and transit time, a potential
benefit of scFOS ingestion could be colon cancer preven-
tion, in particular in the elderly, who are particularly at
risk of developing colon cancer [16].
Although colonic microbiota is relatively stable through-
out adult life, age-related changes in the gastrointestinal
tract inevitably affect its composition [17]. Bifidobacteria
are numerically important colonic species that can be
found in adults [18], and the decline in bifidobacteria
numbers is one of the most marked changes in the elderly
gut [19]. These changes, along with general reduction in
species diversity in most bacterial groups, as well as
changes in diet and digestive physiology, such as intesti-
nal transit time, may result in increased putrefaction in
the colon, and greater susceptibility to disease. Dietary
supplements containing prebiotics have been suggested to
counteract these changes in the elderly [20-22].
In that context, the aim of our study was to assess in
healthy elderly the effects of four-week scFOS ingestion
on colonic microflora and oro-fecal transit time (OFTT).
Methods
Subjects
Twelve elderly healthy volunteers, six men and six
women, aged 69 ± 2 years, participated in the study. None
of them had any gastrointestinal disease history. No anti-
biotics or laxatives had been taken during the 3 months
before the study. No other medication was allowed during
the investigation period. The subjects signed a written
informed consent to the protocol, which was approved by
Lariboisière – Saint-Louis Hospital Ethics Committee.
Study Design
The study was conducted in Saint-Lazare Hospital, Paris,
France. It was divided into three periods: basal (weeks
1–2), scFOS (weeks 3–6), and follow-up (weeks 7–10)
periods. Throughout the study, volunteers took their
usual diet. Neither fermented dairy products containing
viable bifidobacteria and FOS (onions, asparagus, rye,
and Jerusalem artichoke) were allowed, nor food known
to induce abdominal symptoms (beans, cabbage, raisin,
banana, and wheat bran). During scFOS period, subjects
received 8 g/d scFOS in two oral doses at the end of break-
fast and diner. This dose was defined as a good compro-
mise between efficacy and tolerance. We used scFOS from
Actilight® (Beghin Meiji, Marckolsheim, France), which
consist of 44% 1-ketose (GF2), 46% nystose (GF3), and
10% 1F-β-fructofuranosyl nystose (GF4).
To measure the mean oro-fecal transit time (OFTT), the
subjects ingested, with their breakfast, 20 radio-opaque
pellets of different shapes for three consecutive days [23].
The first stools passed after the fourth day were collected,
and their marker content analysed. Stools had been col-
lected for three consecutive days before the end of weeks
2 (basal period), 6 (ingestion period), and 10 (follow-up
period), that is to say at the end of each feeding period.
Tolerance to administered scFOS was evaluated using a
daily chart in which the symptoms (excessive flatus, bor-
borygmi, bloating, and abdominal pain) were rated from
zero (no symptom) to three (severe symptom). Stool fre-
quency and consistency were also graded by the volun-
teers. Diarrhoea was defined as one or more watery stools,
or more than three stools per day.
Stool collection
Stools were collected three times, for 48 h at the end of
each period (weeks 2, 6, and 10). Samples were collected
in plastic containers rendered anaerobic (Anaerocult A;
Merck, Darmstadt, Germany), immediately transferred to
the laboratory, and then analysed for bacterial counts andNutrition Journal 2007, 6:42 http://www.nutritionj.com/content/6/1/42
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pH within 2 hours. Stools were then frozen at -20°C for
further analysis.
Bacterial counts and pH
Fresh faecal samples (1 g) were introduced in the first pre-
weighed tube of the dilution series and thoroughly mixed,
then further tenfold dilutions were made up to -9 in a
reduced diluent (1/4 strength cysteinated Ringer diluent).
0.1 ml of each dilution was spread on plates with different
selective media to distinguish several bacterial genera:
total anaerobic counts (Wilkins-Chalgren agar), Bifido-
bacterium (Beerens' medium), Clostridium spp. (TNS
medium), and enterobacteria (McConkey agar). The tests
were duplicated for the first two media. Plates of the first
three media were anaerobically incubated for 5 to 7 d, and
McConkey agar was aerobically incubated for 48 hours.
Colony counts were obtained and expressed as a log of the
colony-forming units (CFU) per gram of fresh faeces.
Extemporarily, the fresh stool pH was measured by pH
meter (Bioblock, Illkirch, France).
Bile acids
For bile acid and neutral sterol analysis, frozen stools had
been lyophilised and lipids had been extracted with etha-
nol for 24 hours in a Soxhlet apparatus. Lipid fractions
had been saponified in boiling ethanolic 2 m potassium
hydroxide for 1 h. Sterols were extracted with hexane, and
bile acids were deconjugated. [24] Total bile acids were
measured by 3-hydroxy-steroid-dehydrogenase, according
to slight modification of Stempfel and Sidbury technique
[25]. Prior to enzyme determination, bile acids were dis-
solved in 2-propanol. Free bile acids were methylated
with diazomethane, silylated with Deriva-sil
(Chrompack, Middelburg, The Netherlands), and assayed
on Carlo Erba (Milan, Italy) HGRC 5160 gas chromato-
graph equipped with standard fused silica WCOT capil-
lary column cross-linked with OV1701 (Spiral, Dijon,
France) (length, 25 m; film thickness, 0.2 lm; oven tem-
perature, 240°C; hydrogen carrier gas flow rate, 2 mL/
min). Faecal sterols were silylated with bis(trimethylsi-
lyl)tri-fluoroacetamide (BSTFA) + 1% trimethylchlorosi-
lane (TMCS) (Pierce, Rockford, IL, USA), and quantified
using gas chromatography described above, with the fol-
lowing modifications: fused silica WCOT OV 101 capil-
lary column (Spiral, Dijon, France) (length, 25 m; film
thickness, 0.2 lm; oven temperature, 220°C).
Data analysis
Faecal bacteria concentrations were expressed as log col-
ony forming unit (cfu)/g wet weight. The results were
expressed as means ± SEM for each period. Two-way
ANOVA, with time and treatment as factors, was used to
compare bacterial concentrations, pH, and faecal metabo-
lites between the three periods. Following a significant F
test (P < 0.05), Newman-Keuls test was used to identify
differences between individual means. Symptoms experi-
enced with scFOS were compared to those experienced
with placebo using Wilcoxon signed rank test.
Results
Bacterial counts and pH
Table 1 summarises bacterial counts and pH during basal,
scFOS, and follow-up periods. Faecal bifidobacteria
counts were significantly increased during the scFOS
period (9.17 ± 0.17 log cfu/g vs 8.52 ± 0.26 log cfu/g dur-
ing the basal period; P < 0.05), and returned to their base-
line values during the follow-up period (8.37 ± 0.21 log
cfu/g). Total anaerobe counts did not change during
scFOS period compared to the basal period, but decreased
in the follow-up period compared to the ingestion period
(P < 0.05). Faecal Clostridium counts were significantly
increased during the follow-up period compared to the
basal and scFOS periods (P < 0.05). Faecal enterobacteria
counts did not change during the three periods. Faecal pH
tended to decrease during scFOS and follow-up periods
compared to the basal period (P = 0.06).
Faecal neutral sterols and bile acids
Faecal cholesterol concentration increased during the
scFOS period (8.18 ± 2.37 mg/g dry matter vs 2.81 ± 0.94
mg/g dry matter during the basal period; P < 0.05)), and
returned to the baseline value during the follow-up period
(2.87 ± 0.44 mg/g dry matter (figure 1). However, no sta-
tistical differences were reported for coprostanol,
cholestanol, and ketones for the three periods (Table 2).
Total neutral sterol concentrations and outputs did not
change, but tended to increase (p = 0.08) during the
scFOS period.
Total bile acid concentrations and outputs were similar in
the three periods. Concentrations of secondary (litho-
cholic and deoxycholic acids) and primary bile acids
(cholic and chenodeoxycholic acids) did not change for
the three periods (Table 2).
Table 1: Faecal bacterial counts (log cfu/g wet weight) and pH in 
elderly healthy volunteers during basal (2 wks), scFOS (4 wks) 
and follow-up (4 wks) periods (n = 12, mean ± SEM)
Basal period scFOS period Follow-up 
period
Bifidobacteria 8.52 ± 0.26 9.17 ± 0.17a 8.37 ± 0.21
Total anaerobes 10.09 ± 0.07 10.22 ± 0.06b 9.94 ± 0.09
Clostridium 3.25 ± 0.25 3.45 ± 0.26b 4.29 ± 0.30c
Enterobacteria 7.69 ± 0.21 7.45 ± 0.28 7.48 ± 0.24
PH 6.57 ± 0.10 6.32 ± 0.10 6.26 ± 0.07
a different from basal and follow-up periods (P < 0.05)
b different from follow-up period (P < 0.05)
c different from basal period (P < 0.05)Nutrition Journal 2007, 6:42 http://www.nutritionj.com/content/6/1/42
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Stool weight and oro-fecal transit time
Stool wet weight, dry matter, and faecal water did not
change throughout the study. Oro-fecal transit time was
not significantly modified by scFOS ingestion compared
to the basal and follow-up periods (Table 3).
Digestive tolerance
During scFOS ingestion, excessive flatus and bloating
were significantly more frequent when compared to the
basal period (P < 0.05), but symptom intensity was very
mild (Table 4). Borborygmi and abdominal pain were not
significantly different in all periods.
Discussion
The present experiment showed that four-week scFOS
ingestion, with a dose of 8 g/d, is well tolerated and leads
Table 3: Mean oro-fecal transit time (OFTT) and mean 24-h 
faecal wet weight, dry weight and percentage of faecal water in 
elderly healthy volunteers during the basal (2 wks), scFOS (4 
wks) and follow-up (4 wks) periods (n = 12, mean ± SEM)
Basal period scFOS period Follow-up 
period
OFTT (h) 37.2 ± 3.4 39.9 ± 3.3 37.8 ± 3.7
Wet weight (g/d) 155.4 ± 20.9 137.7 ± 17.3 174.8 ± 22.0
Dry weight (g/d) 32.8 ± 3.3 28.8 ± 2.9 35.2 ± 3.5
Faecal water (%) 77 ± 2 77 ± 1 76 ± 2
Table 2: Faecal neutral sterols and bile acids (mg/g dry matter) in 
elderly healthy volunteers during the basal (2 wks), scFOS (4 wks) 
and follow-up (4 wks) periods (n = 12, mean ± SEM)
Neutral sterols Basal period scFOS period Follow-up 
period
Coprostanol 9.00 ± 1.40 8.29 ± 2.09 7.99 ± 1.62
Cholestanol 0.29 ± 0.11 0,13 ± 0.05 0.23 ± 0.17
Cholesterol 2.81 ± 0.94a 8.18 ± 2.37b 2.87 ± 0.44a
Ketones 0.27 ± 0.05 0.16 ± 0.08 0.21 ± 0.06
Total 12.38 ± 1.15 16.75 ± 1.94 11.30 ± 1.57
Bile acids Basal period scFOS period Follow-up 
period
Lithocholic 2.00 ± 0.43 1.29 ± 0.29 1.26 ± 0.17
Deoxycholic 1.80 ± 0.35 2.58 ± 0.50 2.61 ± 0.63
Cholic 0.46 ± 0.21 0.58 ± 0.19 0.87 ± 0.24
Chenodeoxycholic 0.24 ± 0.05 0.20 ± 0.04 0.30 ± 0.07
Ketones 1.26 ± 0.30 1.52 ± 068 1.33 ± 0.19
Total 5.77 ± 0.66 6.17 ± 1.25 6.37 ± 1.02
a ≠ b : P < 0.05
Effect of 4-wk scFOS ingestion (8 g/d) on faecal cholesterol in healthy volunteers (means ± SEM, n = 12) Figure 1
Effect of 4-wk scFOS ingestion (8 g/d) on faecal cholesterol in healthy volunteers (means ± SEM, n = 12). *P < 
0.05 between scFOS period and both basal and follow-up period
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to significant increase in faecal bifidobacteria and choles-
terol excretion in healthy elderly. The sc-FOS bifidogenic
effect has been extensively demonstrated in adults [6,26-
28], but rarely in elderly [19,21,22]. Among the very few
available studies about functional foods in elderly, one
recent double-blind trial testing a symbiotic (B. lactis BL-
01, B. bifidum BB-02 and an inulin-based prebiotic) also
found promising results [29]. Significant increase in total
bifidobacteria counts was indeed observed in the symbi-
otic group compared with the placebo group.
We also found increasing Clostridium spp. after sc-FOS
ingestion discontinuation. Clostridium spp. is a major com-
ponent of normal anaerobic microflora and it can not be
considered as a deleterious or beneficial genus. Since
some toxinogenic subspecies of Clostridium difficile are
related to an increased risk of pseudo membranous colitis
and/or infection in older people, it would have been inter-
esting to measure the sc-FOS effects on these subspecies.
However, we did not perform those analyses, for they
were out of our study scope. Further studies may investi-
gate this point, using adequate measurement methods for
species concentrations and toxinogenic properties (cellu-
lar cultures, biomolecular analysis). Culture-based enu-
meration of microbiota does not usually allow for
bacterial species measurement, but mainly bacterial
genus.
In our study, several parameters were assessed with the
objective to better understand scFOS physiological effects
in healthy elderly, such as transit time, stool characteris-
tics, and colonic environment. We did not find scFOS
ingestion changed faecal weight and oro-fecal transit time
in elderly. Gibson et al. have shown that prebiotics can
increase stool output: they studied 8 volunteers under
controlled diet, and showed that with 15 g/d fructo-oli-
gosaccharides, stool output significantly increased from
136 to 154 g/d [27]. Other two human studies did not
demonstrate increasing stool output [2,30]. but the diet
was not controlled in none of these studies, which may
have hidden any slight effect. In the study of Alles et al., 12
healthy subjects were given 4.8–19.2 g/d oligomate (52%
galacto-oligosaccharides), which did not result in any
change in bowel habit. However, the subjects started with
unusually high faecal weights under controlled diet, 272
± 26 g/d On the other hand, studies using probiotics dem-
onstrated bifidobacteria could reduce human colonic
transit time, but not all bifidobacteria strains have the
same effects [31]. This specific strain-dependent effect
could explain the reason why our prebiotic, which stimu-
lates global endogenous bifidobacteria, had no effect.
In our study, the microbial transformation of cholesterol
into coprostanol was not influenced by scFOS ingestion.
Another study observed that sterol and fatty acid biohy-
drogenation by intestinal microflora is altered by oli-
gosaccharide fermentation [32]. Coprostanol production
results from intestinal anaerobic bacteria action [33].
Concerning bile acid metabolism, no differences were
observed during the three periods. Furthermore, the use of
poorly digestible carbohydrates in rats, hamsters and pigs
demonstrated that prevention of microbial conversion of
bile acids depended on the carbohydrate dose in the diet
[23,34] This suggests that the low carbohydrate dose, 8 g/
d scFOS, used in this experiment is unable to modify
microbial conversion of bile acids.
Endogenous or exogenous bile acids, as well as dietary
cholesterol are carcinogenic factors involved in colon can-
cer in laboratory animals [35,36] Various epidemiological
studies suggest those steroids could also be involved in
colon cancer in men [12,37]. According to these studies,
low scFOS dose ingestion by humans, which prevented
microbial conversion of cholesterol into cytotoxic mole-
cule, (coprostanol, potentially carcinogenetic), could be
interesting for humans. In our study, the intake of 8 g/d
scFOS led to increasing faecal cholesterol. The mechanism
of such increase could be related to decreasing cholesterol
bacterial transformation, although we failed to find any
significant sc-FOS effect on cholesterol bacterial metabo-
lism. Moreover, the low scFOS dose used in our study was
also probably not sufficient to significantly reduce micro-
bial conversion of bile acids. However, in our previous
study evaluating a higher scFOS dose (12.5 g/d), we also
failed to show any significant effect in bile acids and neu-
tral sterol [28]. These negative results could be explained
by a questionable capacity of various bifidobacteria to
take up cholesterol into their cellular membrane [38].
Conclusion
Overall, we showed that 8 g/d scFOS ingested are well tol-
erated and led to significant increase in faecal bifidobacte-
ria in healthy elderly. Under our experimental conditions,
i.e. 8 g/d for 12 days, we failed to show any sc-FOS effects
on OFTT, which is commonly increased in elderly living
Table 4: Digestive symptom intensity (ranged from 0 to 3) in 
elderly health volunteers during the basal (2 wks), scFOS (4 wks) 
and follow-up (4 wks) periods (n = 12, mean ± SEM)
Basal period scFOS period Follow-up 
period
Excessive flatus 0 0,83 ± 0,3a 0,25 ± 0,13
Bloating 0 0,67 ± 0,26a 0,33 ± 0,14
Borborygmi 0 0 0
Abdominal 
pain
0 0,42 ± 0,23 0,25 ± 0,13
Symptom intensity was rated as follow: 0: no symptom ; 1: mild 
symptoms; 2: moderate symptoms; 3: severe symptoms
a different from basal period (P < 0.05)Nutrition Journal 2007, 6:42 http://www.nutritionj.com/content/6/1/42
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in industrialised countries. We found significant change
in cholesterol metabolism, which could potentially exert
protective action against colon cancer; however, this find-
ing warrants further studies.
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